Recent Company News

• 04:48 AM ET Oct 08, 2026
  

  China's NMPA approves Daiichi Sankyo's Datroway for adults with unresectable or metastatic TNBC (¥2653.5000, 0)

• 04:46 AM ET Oct 08, 2026
  

  China's NMPA approves Daiichi Sankyo's Enhertu as adjuvant treatment of adults with HER2-positive early breast cancer (¥2653.5000, 0)

• 08:30 PM ET Oct 06, 2026
  

  NICE recommends Daiichi Sankyo's Enhertu to treat HER2-low metastatic or unresectable breast cancer after chemotherapy (¥2724.0000, -28)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 02:40 AM ET Oct 02, 2026
  

  Daiichi Sankyo, AstraZeneca sign clinical trial collaboration agreement with Summit Therapeutics for Datroway combined with ivonescimab for multiple tumor types

• 04:54 PM ET Sep 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:45 AM ET Sep 28, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 11:01 PM ET Sep 27, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 10:56 PM ET Sep 27, 2026
  

  Quick Take - Daiichi Sankyo trading lower (2.9%); I-DXd US filing withdrawal seen pushing out approval timeline (¥2844.5000, -84.5)

• 04:34 PM ET Sep 25, 2026
  

  Merck and Daiichi Sankyo voluntarily wthdrawal Biologics License Application for Ifinatamab Deruxtecan in certain Patients with Previously Treated ES-SCLC ($148.78, 0.00)